Lakefront Biotherapeutics (LKFT) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Lakefront Biotherapeutics (LKFT) over the past year, gaining 30.6% versus a loss of 14.5%. Over five years, TRVI leads with a +918.6% price change compared with -44.9% for LKFT. Lakefront Biotherapeutics is the larger company by market cap ($1.93 billion vs $1.83 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LKFT | TRVI |
|---|---|---|
| Share price | $29.51 | $12.83 |
| Market cap | $1.93B | $1.83B |
| 1-day change | -1.63% | -2.40% |
| YTD return | -9.76% | +2.44% |
| 1-year return | -14.46% | +30.60% |
| 5-year return | -44.86% | +918.60% |
| P/E ratio (TTM) | 2.81 | — |
| EPS (TTM) | $10.52 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.24 | $20.22 |
| 52-week low | $25.68 | $9.28 |
| Distance from 52-week high | -18.57% | -36.57% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +2.27% | +119.73% |
| Average volume | 273.30K | 1.95M |
| Shares outstanding | 65.48M | 142.48M |
| Employees | 196 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRVI has outperformed LKFT by 45.1 percentage points over the past year.
About Lakefront Biotherapeutics
LKFT stock →Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 196 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
LKFT vs TRVI FAQ
Which is bigger, Lakefront Biotherapeutics or Trevi Therapeutics?
Lakefront Biotherapeutics (LKFT) is larger, with a market capitalization of $1.93B compared with $1.83B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, LKFT or TRVI?
TRVI returned +30.60% over the past 12 months, compared with -14.46% for LKFT (price return, excluding dividends). Past performance does not predict future results.
Are Lakefront Biotherapeutics and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.